Sugi Predict

Sugi Predict / Compounds / SCHEMBL1157716

SCHEMBL1157716

SCHEMBL1157716

CCS(=O)(=O)Nc1c[c]ccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 6/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ NR3C2 P08235 1/20 0.44
▸ PSIP1 O75475 1/20 0.41
▸ AR P10275 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ KIF11 P52732 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ AURKA O14965 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ AURKB Q96GD4 1/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ ADRA2A P08913 1/20 0.38
▸ ADRA1A P35348 1/20 0.38
▸ PARP1 P09874 1/20 0.37
▸ PGR P06401 1/20 0.37
▸ BRDT Q58F21 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161048 0.88 KDR (0.42) HPGDLMNAHTTSMN1; SMN2AR
SCHEMBL9850091 0.85 AR (0.47) HPGDLMNAHTTARMAPT
SCHEMBL1419122 0.84 LMNA (0.31) HPGDLMNAHTTSMN1; SMN2
SCHEMBL9864043 0.82 GGPS1 (0.44) HPGDLMNAARAURKAKDR
SCHEMBL11478431 0.82 GGPS1 (0.44) HPGDLMNAARAURKAKDR
SCHEMBL8744668 0.82 GGPS1 (0.44) HPGDLMNAARAURKAKDR
SCHEMBL8957580 0.82 GGPS1 (0.44) HPGDLMNAARAURKAKDR
SCHEMBL183564 0.81 KEAP1 (0.57) HPGDLMNAHTTSMN1; SMN2NR3C2
SCHEMBL1418868 0.81 IKBKB (0.34) —
SCHEMBL27428805 0.80 HPGD (0.70) HPGDLMNAHTTSMN1; SMN2NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 — — EP claimed
US-8772307-B2 Substituted spiro compounds and their use for producing pain-relief medicaments GRUENENTHAL GMBH (DE) 2014-07-08 — — US claimed
CN-103717574-A Novel compounds and compositions for the inhibition of nampt FORMA TM LLC 2014-04-09 — — CN claimed
US-7981883-B2 Substituted spiro-compounds and the use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-07-19 — — US claimed
US-20110046146-A9 Phosphodiesterase 4 inhibitors SCHUMACHER RICHARD A 2011-02-24 — — US claimed
EP-1569908-B1 PYRIDINE N-OXIDE COMPOUNDS AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARM CORP (US) 2010-09-15 — — EP claimed
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments GRUENENTHAL GMBH (DE) 2009-11-05 — — US claimed
CN-100513397-C Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors MEMORY PHARM CORP (US) 2009-07-15 — — CN claimed
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders GRUENENTHAL GMBH (DE) 2008-10-30 — — US claimed
CN-100378075-C Aniline derivatives useful as phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS INC (US) 2008-04-02 — — CN claimed
CN-1498211-A Aniline derivative using as phosphodiesterase 4 inhibitor ����˹��ҩ�﹫˾ 2004-05-19 — — CN claimed
US-6699890-B2 N-SUBSTITUTED DIETHER ANILINE AND DIETHER DIPHENYLAMINE DERIVATIVES MEMORY PHARMACEUTICALS CORP. 2004-03-02 — — US claimed
EP-1353907-A2 PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceutical Corporation (US) 2003-10-22 — — EP claimed
US-20030149052-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. 2003-08-07 — — US claimed
US-20020151566-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORP. (US) 2002-10-17 — — US claimed
WO-2002074726-A2 ANILINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2002-09-26 — — WO claimed
EP-1192132-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-04-03 — — EP claimed
EP-1192135-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2002-04-03 — — EP claimed
WO-2000076970-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 — — WO claimed
WO-2000076971-A2 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2000-12-21 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments REN, PKD1, PKD2 HPGD 90/4885LMNA 404/4885HTT 1703/4885
US-20030149052-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A HPGD 483/4885LMNA 3520/4885HTT 4575/4885
US-20020151566-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3A HPGD 483/4885LMNA 3520/4885HTT 4575/4885
US-20110046146-A9 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE3B HPGD 436/4885LMNA 3756/4885HTT 4254/4885
US-20080269271-A1 Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders INA, SCN1A, SI HPGD 1142/4885LMNA 875/4885HTT 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.